View all MBCC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Acelity, Astellas, AstraZeneca, Celgene, Eisai Inc., Genentech, Inc., Genomic Health, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, and TESARO, Inc.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference® - PER Pulse™ Recap
PER Pulse™ Recap

Resources

Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®
Earn up to 2.0 AMA PRA Category 1 Credits™
In this episode of Clinical Case Vignette Series™: 33rd Annual Miami Breast Cancer Conference®, content from this year's conference held on March 11-13, 2016, will be covered. This activity consists of a series of interviews with renowned experts Elizabeth Mittendorf, MD, PhD, and Andrew D. Seidman, MD, which explore topics that are clinically relevant to the practicing community clinician. Important topics that are key to evolving treatment paradigms for patients with breast cancer are reviewed, such as the management of HR+/HER2+ locally invasive disease and axilla in early-stage clinically node-negative disease. A look at some of the more exciting emerging strategies in the field are also reviewed, including an update on vaccine development for HER2+ disease and immune checkpoint blockade in the setting of triple-negative breast cancer.

PER Pulse™ Recap
PER Pulse™ Recaps for Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference® focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspectives on case management decisions is provided in these summaries.



PER Pulse™ Recap

PER Pulse™ Recap
 


1 of 3
PER Pulse™ Recap

Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference® is a series of short video interviews with faculty from the conference who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features discussion on:

  • Breast cancer vaccines, by Elizabeth Mittendorf, MD, PhD
  • Immune checkpoint blockade in triple-negative breast cancer, by Elizabeth Mittendorf, MD, PhD
  • Management of axilla in early-stage, clinically node-negative breast cancer, by Elizabeth Mittendorf, MD, PhD
  • Systemic therapy for hormone receptor–positive, HER2-positive, locally invasive breast cancer, by Andrew Seidman, MD

See more at http://www.gotoper.com/online-cme-activities/mbcc/clinical-vignette-series-33rd-annual-miami-breast-cancer-conference

Throughout the activity, these physicians answer questions about their decisions for managing cases, and offer perspectives and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Mittendorf’s answers to questions about vaccine therapy for breast cancer. During her interview, Dr. Mittendorf:

  • Reviews the rationale behind ongoing investigations of breast cancer vaccines in both the adjuvant and metastatic settings, as well as recent clinical trial data and ongoing studies
  • Discusses patient- and disease-related factors to consider when selecting patients for vaccine clinical trials
  • Explains that, to date, benefits from breast cancer vaccines have been demonstrated only in the disease-free, adjuvant setting. The breast cancer vaccine furthest along in clinical development is nelipepimut-S, an anti-HER2 vaccine currently in phase III clinical trial for secondary prevention of recurrence in patients who are disease-free after receiving standard therapy for HER2 1+/2+ node-positive breast cancer
  • Offers guidance to community oncologists interested in exploring vaccine clinical trials for their patients
  • Shares her perspectives on the future of breast cancer vaccines

2 of 3
PER Pulse™ Recap

Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference® is a series of short video interviews with faculty from the conference who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features discussion on:

  • Breast cancer vaccines, by Elizabeth Mittendorf, MD, PhD
  • Immune checkpoint blockade in triple-negative breast cancer, by Elizabeth Mittendorf, MD, PhD
  • Management of axilla in early-stage, clinically node-negative breast cancer, by Elizabeth Mittendorf, MD, PhD
  • Systemic therapy for hormone receptor (HR)–positive, HER2-positive, locally invasive breast cancer, by Andrew Seidman, MD

See more at http://www.gotoper.com/online-cme-activities/mbcc/clinical-vignette-series-33rd-annual-miami-breast-cancer-conference

Throughout the activity, the faculty answer questions about their management decisions and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Seidman’s answers to questions related to a case of HR-positive, HER2-positive, locally invasive breast cancer. During his interview, Dr. Seidman:

  • Reviews key patient and disease factors that influence his decisions regarding neoadjuvant therapy, including the importance of accurate staging and assessments to conduct prior to initiation of chemotherapy and anti-HER2 therapies
  • Explains his neoadjuvant regimen of choice in this setting in the context of clinical trial data
  • Discusses the significance of pathologic complete response as an outcome and related clinical trial data, including those of TRYPHAENA, NeoSphere, as well as a retrospective analysis of a Memorial Sloan Kettering Cancer Center cohort that received doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab
    • Based on these data, he would not select patients for neoadjuvant pertuzumab based on HR status
  • Shares his perspectives on the study of ado-trastuzumab emtansine (T-DM1) in earlier stages of estrogen receptor–positive breast cancer, and on targeting downstream HER2 signaling (eg, mTOR, AKT, PI3K)

3 of 3
PER Pulse™ Recap

Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®is a series of short video interviews with faculty from the Conference who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features commentary on:

  • Breast cancer vaccines, by Elizabeth Mittendorf, MD, PhD
  • Immune checkpoint blockade in triple-negative breast cancer (TNBC), by Elizabeth Mittendorf, MD, PhD
  • Management of axilla in early-stage, clinically node-negative breast cancer, by Elizabeth Mittendorf, MD, PhD
  • Systemic therapy for hormone receptor‒positive, HER2-positive, locally invasive breast cancer, by Andrew Seidman, MD

- See more at: http://www.gotoper.com/online-cme-activities/mbcc/clinical-vignette-series-33rd-annual-miami-breast-cancer-conference

Throughout the activity, the faculty answer questions about their management decisions, and offer perspective and guidance on issues important to community-based physicians.
This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Mittendorf’s answers to questions related to the use of immune checkpoint blocking agents for TNBC. During her interview, Dr. Mittendorf discusses:

  • Ongoing clinical trials involving immune checkpoint blocking agents (eg, pembrolizumab, atezolizumab) for TNBC and other subtypes of breast cancer, as well as key similarities and differences between the experimental agents
  • Rationales for using immune checkpoint blocking agents alone and in combination for breast cancer (eg, with nab-paclitaxel, cryotherapy, vaccines)
  • Potential strategies for immune-based therapies beyond PD-L1, PD-1, and CTLA4 blockade
  • Notable immune-related adverse events observed among breast cancer patients on these trials
  • Anticipated clinical trial data

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Supported by educational grants from AbbVie, Acelity, Astellas, AstraZeneca, Celgene, Eisai Inc., Genentech, Inc., Genomic Health, Inc., Lilly, Novartis Pharmaceuticals Corporation, Pacira Pharmaceuticals, Inc., Pfizer, and TESARO, Inc.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
 





Calendar of Events
Filter By